KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non–Small Cell Lung Cancer
Source: View publication →
The addition of pembrolizumab to stereotactic body radiotherapy (SBRT) in patients with unresected stage I or II non-small cell lung cancer failed to improve event-free survival and significantly increased severe and fatal treatment-related toxicity, leading to early trial termination.
Key Findings
Study Design
Study Limitations
Clinical Significance
KEYNOTE-867 provides a definitive cautionary answer regarding the integration of immune checkpoint blockade with definitive SBRT in early-stage, inoperable NSCLC. The failure to meaningfully prolong EFS, coupled with a five-fold increase in severe toxicities and a clear signal for treatment-related mortality, firmly establishes that pembrolizumab should not be routinely added to SBRT in this frail population. It challenges the assumption that highly active systemic agents in advanced disease seamlessly translate into benefit in early-stage inoperable settings.
Historical Context
Stereotactic body radiotherapy (SBRT) is the well-established standard of care for patients with early-stage NSCLC who are medically inoperable or decline surgery, offering excellent local control but leaving patients vulnerable to distant recurrence. The revolutionary success of immune checkpoint inhibitors in both advanced NSCLC and locally advanced disease (such as durvalumab consolidation post-chemoradiation in the PACIFIC trial) fueled hypotheses that concurrent PD-1 blockade might eliminate micrometastases post-SBRT. While successful in neoadjuvant resectable disease (KEYNOTE-671), KEYNOTE-867 highlights the critical biological and clinical distinctions in the medically inoperable cohort, where additive toxicities overwhelmingly negated unproven systemic benefits.
Guided Discussion
High-yield insights from every perspective
What is the mechanism behind the increased risk of severe pulmonary toxicity when combining thoracic stereotactic body radiotherapy (SBRT) with a PD-1 inhibitor like pembrolizumab?
Key Response
Both SBRT and PD-1 inhibitors can independently cause pneumonitis. SBRT damages alveolar pneumocytes, releasing damage-associated molecular patterns and activating local immune responses. PD-1 inhibitors remove T-cell inhibition, which can amplify this localized radiation-induced inflammation into a severe, life-threatening immune-related pneumonitis.
Based on the KEYNOTE-867 trial, how does the management of a medically inoperable patient with Stage I NSCLC differ from a patient with Stage III NSCLC regarding the integration of immunotherapy and radiation?
Key Response
While the PACIFIC trial established consolidation immunotherapy after conventional chemoradiation as the standard of care for unresectable Stage III NSCLC, KEYNOTE-867 demonstrated that adding pembrolizumab to SBRT in Stage I or II medically inoperable NSCLC yields no event-free survival benefit and increases fatal toxicity. Thus, Stage I or II patients should receive SBRT alone.
The PACIFIC trial showed a survival benefit with immunotherapy after conventionally fractionated radiation in Stage III NSCLC, whereas KEYNOTE-867 failed with SBRT in early-stage disease. What biological and dosimetric factors might explain this discrepancy?
Key Response
Stage I or II disease has a lower burden of micrometastatic disease, reducing the potential absolute benefit of systemic therapy. Furthermore, SBRT utilizes extreme hypofractionation, which causes distinct vascular damage and massive localized antigen release compared to conventional fractionation. This massive local injury, when combined with concurrent PD-1 blockade, may cross the threshold into fatal hyperinflammatory pneumonitis without enhancing systemic anti-tumor immunity.
How can the early termination of KEYNOTE-867 be utilized to counsel early-stage oncology patients who advocate for maximum therapy or off-label use of checkpoint inhibitors?
Key Response
KEYNOTE-867 serves as a critical paradigm that in oncology, 'more is not always better'. Combining highly active modalities without Phase III safety and efficacy data can lead to synergistic fatal toxicities without improving survival. It highlights the importance of the therapeutic index and the necessity of adhering to evidence-based medicine in early-stage, potentially curable disease.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
KEYNOTE-867 was terminated early for both futility and toxicity. How do modern trial designs incorporate continuous toxicity monitoring boundaries alongside traditional efficacy boundaries when evaluating novel combinations?
Key Response
Traditional designs evaluate efficacy at discrete interim analyses, but novel combinations require Bayesian continuous safety monitoring or sequential probability ratio tests to stop a trial instantly if severe adverse event rates exceed predefined unacceptable thresholds. This ensures patient safety is prioritized before waiting for mature event-free survival data to cross futility boundaries.
When reviewing a manuscript reporting on combined SBRT and immunotherapy, what methodological safeguards must be present to ensure the accurate attribution of severe adverse events, particularly pneumonitis?
Key Response
A stringent review requires the trial to use a blinded independent central review committee to adjudicate toxicity. Distinguishing radiation pneumonitis from immune-related pneumonitis or infection is notoriously difficult radiographically and clinically. Misclassification can obscure the true safety profile of the combination, making independent, standardized adjudication essential for internal validity.
How should organizations like ASCO and NCCN integrate the findings of KEYNOTE-867 into their clinical practice guidelines for early-stage NSCLC?
Key Response
Current guidelines recommend SBRT as the primary treatment for medically inoperable Stage I or II NSCLC. KEYNOTE-867 provides Level 1 evidence from a randomized, double-blind Phase III trial to create a strong, explicit recommendation against the concurrent use of pembrolizumab with SBRT in this population due to the lack of event-free survival benefit and the significant increase in severe and fatal toxicities.
Clinical Landscape
Noteworthy Related Trials
PACIFIC Trial
Tested
Durvalumab for up to 12 months
Population
Patients with stage III, unresectable NSCLC post-chemoradiotherapy
Comparator
Placebo
Endpoint
Progression-free survival (PFS) and overall survival (OS)
PEMBRO-RT
Tested
Pembrolizumab preceded by SBRT (3 doses of 8 Gy)
Population
Patients with advanced NSCLC
Comparator
Pembrolizumab alone
Endpoint
Overall response rate (ORR) at 12 weeks
PEARLS/KEYNOTE-091
Tested
Pembrolizumab 200 mg every 3 weeks
Population
Patients with completely resected stage IB to IIIA NSCLC
Comparator
Placebo
Endpoint
Disease-free survival (DFS)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis